Epidemiological Profile of Salivary Gland Tumors in Southern Iranian Population: A Retrospective Study of 405 Cases

Table 2

Histopathology and gender distribution of benign and malignant SGTs.

		%^a	%^b	Sex
				Male		Female
					%^a		%^a
Benign
Pleomorphic adenoma	213	52.5	70.5	69	17	144	35.5
Warthin’s tumor	65	16	21.5	59	14.5	6	1.4
Basal cell adenoma	15	3.7	4.9	5	1.2	10	2.4
Myoepithelioma	4	0.9	1.3	2	0.4	2	0.4
Oncocytoma (oxyphilic adenoma)	3	0.7	0.9	2	0.4	1	0.2
Monomorphic adenoma	2	0.4	0.6	1	0.2	1	0.2
Total	302	74.5	100	138	34	164	40.4
Malignant
Mucoepidermoid carcinoma	27	6.6	26.2	11	2.7	16	3.9
Adenoid cystic carcinoma	23	5.6	22.3	7	1.7	16	3.9
Acinic cell carcinoma	14	3.4	13.5	6	1.4	8	1.9
Salivary duct carcinoma	8	1.9	7.7	6	1.4	2	0.4
Lymphoma	6	1.4	5.8	2	0.4	4	0.9
Malignant mixed tumor	5	1.2	4.8	2	0.4	3	0.7
Carcinoma ex pleomorphic adenoma	4	0.9	3.8	2	0.4	2	0.4
Basal cell adenocarcinoma	3	0.7	2.9	1	0.2	2	0.4
Poorly differentiated carcinoma	3	0.7	2.9	2	0.4	1	0.2
Epithelial myoepithelial carcinoma	3	0.7	2.9	2	0.4	1	0.2
Hyalinizing clear cell carcinoma	1	0.2	0.9	1	0.2	0	0
Oncocytic carcinoma	1	0.2	0.9	1	0.2	0	0
Papillary carcinoma	1	0.2	0.9	1	0.2	0	0
Papillary adenocarcinoma	1	0.2	0.9	1	0.2	0	0
Adenocarcinoma	1	0.2	0.9	1	0.2	0	0
Small cell neuroendocrine carcinoma	1	0.2	0.9	1	0.2	0	0
Adenosquamous cell carcinoma	1	0.2	0.9	1	0.2	0	0
Total	103	25.4	100	48	11.8	55	13.5

^aPercentage in relation with total number of cases. ^bPercentage in relation with the group (benign/malignant).